• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

庞贝病的分子遗传学:全面概述。

Molecular genetics of Pompe disease: a comprehensive overview.

作者信息

Peruzzo Paolo, Pavan Eleonora, Dardis Andrea

机构信息

Regional Coordinator Centre for Rare Diseases, University Hospital Santa Maria della Misericordia, Udine, Italy.

出版信息

Ann Transl Med. 2019 Jul;7(13):278. doi: 10.21037/atm.2019.04.13.

DOI:10.21037/atm.2019.04.13
PMID:31392190
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6642931/
Abstract

Pompe disease (PD) is an autosomal recessive lysosomal disorder caused by the deficient activity of acid alpha-glucosidase (GAA) enzyme due to mutations in the gene. The enzymatic deficiency leads to the accumulation of glycogen within the lysosomes. Clinically, the disease has been classically classified in infantile and childhood/adult forms. The gene has been localized to chromosome 17q25.2-q25.3 and to date, 582 mutations distributed throughout the whole gene have been reported (HGMD: http://www.hgmd.cf.ac.uk/ac/). All types of mutations have been described; missense variants are the most frequent type followed by small deletions. Most mutations are private or found in a small number of families. However, an exception is represented by the c.-32-13T>G splice mutation that is very common in patients of Caucasian origin affected by the childhood/adult form of the disease, with an allelic frequency ranging from 40% to 70%. In this article, we review the spectrum of mutations, their distribution in different populations, and their classification according to their impact on splicing process, protein expression and activity. In addition, whenever possible, we discuss the phenotype/genotype correlation. The information collected in this review provides an overview of the molecular genetics of PD and can be used to facilitate diagnosis and genetic counseling of families affected by this disorder.

摘要

庞贝病(PD)是一种常染色体隐性溶酶体疾病,由基因中的突变导致酸性α-葡萄糖苷酶(GAA)酶活性缺乏引起。酶缺乏导致糖原在溶酶体内蓄积。临床上,该疾病传统上分为婴儿型和儿童/成人型。该基因已定位到17号染色体q25.2-q25.3,迄今为止,已报道了分布在整个基因中的582种突变(人类基因突变数据库:http://www.hgmd.cf.ac.uk/ac/)。已描述了所有类型的突变;错义变异是最常见的类型,其次是小缺失。大多数突变是私人的或在少数家族中发现。然而,c.-32-13T>G剪接突变是一个例外,它在受儿童/成人型疾病影响的白种人患者中非常常见,等位基因频率在40%至70%之间。在本文中,我们综述了突变谱、它们在不同人群中的分布以及根据它们对剪接过程、蛋白质表达和活性的影响进行的分类。此外,只要有可能,我们就讨论表型/基因型相关性。本综述收集的信息提供了庞贝病分子遗传学的概述,可用于促进受该疾病影响家庭的诊断和遗传咨询

相似文献

1
Molecular genetics of Pompe disease: a comprehensive overview.庞贝病的分子遗传学:全面概述。
Ann Transl Med. 2019 Jul;7(13):278. doi: 10.21037/atm.2019.04.13.
2
GAA gene mutation detection following clinical evaluation and enzyme activity analysis in Azeri Turkish patients with Pompe disease.对患有庞贝病的阿塞拜疆土耳其患者进行临床评估和酶活性分析后,检测 GAA 基因突变。
Metab Brain Dis. 2020 Oct;35(7):1127-1134. doi: 10.1007/s11011-020-00586-3. Epub 2020 Jun 5.
3
Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.新型 GAA 序列变异 c.1211 A>G 降低婴儿和成人发病庞贝病的酶活性,但不降低蛋白表达。
Gene. 2014 Mar 1;537(1):41-5. doi: 10.1016/j.gene.2013.12.033. Epub 2013 Dec 30.
4
Pompe disease: pathogenesis, molecular genetics and diagnosis.庞贝病:发病机制、分子遗传学和诊断。
Aging (Albany NY). 2020 Aug 3;12(15):15856-15874. doi: 10.18632/aging.103794.
5
Novel GAA mutations in patients with Pompe disease.庞贝病患者中的新型酸性α-葡萄糖苷酶基因突变
Gene. 2015 Apr 25;561(1):124-31. doi: 10.1016/j.gene.2015.02.023. Epub 2015 Feb 12.
6
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.具有相同c.-32-13T->G单倍型的庞贝病患者表现出广泛的症状。
Neurology. 2007 Jan 9;68(2):110-5. doi: 10.1212/01.wnl.0000252798.25690.76.
7
Clinical features of Pompe disease.庞贝病的临床特征。
Acta Myol. 2013 Oct;32(2):82-4.
8
Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease. 三名成人生存素病患者成纤维细胞酸性 α-葡萄糖苷酶活性显著降低。
Mol Genet Metab. 2012 Nov;107(3):485-9. doi: 10.1016/j.ymgme.2012.09.003. Epub 2012 Sep 7.
9
[The long-term follow-up of enzyme replacement treatment in late onset Pompe disease].[晚发型庞贝病酶替代治疗的长期随访]
Ideggyogy Sz. 2020 May 30;73(05-06):151-159. doi: 10.18071/isz.73.0151.
10
A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.日本38例庞贝病患者的GAA基因分子分析及临床谱
Mol Genet Metab Rep. 2017 Oct 31;14:3-9. doi: 10.1016/j.ymgmr.2017.10.009. eCollection 2018 Mar.

引用本文的文献

1
Latest Advancements in Treatment Options for Infantile-Onset Pompe Disease: A Comprehensive Narrative Review.婴儿型庞贝病治疗方案的最新进展:一篇全面的叙述性综述
Clin Med Insights Pediatr. 2025 Aug 11;19:11795565251337900. doi: 10.1177/11795565251337900. eCollection 2025.
2
Case Report: Incidental late-onset Pompe disease diagnosis in a man with no clinical and instrumental evidence of neuromuscular dysfunction.病例报告:一名男性患者偶然被诊断为迟发性庞贝病,其无神经肌肉功能障碍的临床及影像学证据。
Front Genet. 2025 Jun 23;16:1574381. doi: 10.3389/fgene.2025.1574381. eCollection 2025.
3
Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease.对30000多名疑似患有庞贝氏病的有症状患者进行GAA的生化和基因检测。
Hum Mutat. 2024 Oct 22;2024:6248437. doi: 10.1155/2024/6248437. eCollection 2024.
4
Rescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNA.使用修饰的U1小核核糖核酸(snRNA)挽救GAA基因常见和罕见的外显子2跳跃变异体
Mol Med. 2025 Feb 4;31(1):45. doi: 10.1186/s10020-025-01090-z.
5
Highlights of Precision Medicine, Genetics, Epigenetics and Artificial Intelligence in Pompe Disease.庞贝病中精准医学、遗传学、表观遗传学和人工智能的亮点
Int J Mol Sci. 2025 Jan 17;26(2):757. doi: 10.3390/ijms26020757.
6
Exploring Quality of Life in Adults Living With Late-onset Pompe Disease: A Combined Quantitative and Qualitative Analysis of Patient Perceptions from Australia, France, Italy, and the Netherlands.探索晚发型庞贝病成年患者的生活质量:对来自澳大利亚、法国、意大利和荷兰患者认知的定量与定性综合分析
J Health Econ Outcomes Res. 2025 Jan 2;12(1):1-12. doi: 10.36469/001c.126018. eCollection 2025.
7
Navigating Pompe Disease Assessment: A Comprehensive Scoping Review.庞贝病评估指南:一项全面的范围综述
Cureus. 2024 Nov 13;16(11):e73593. doi: 10.7759/cureus.73593. eCollection 2024 Nov.
8
Analyzing immune cell infiltrates in skeletal muscle of infantile-onset Pompe disease using bioinformatics and machine learning.利用生物信息学和机器学习分析婴儿期发病庞贝病患者骨骼肌中的免疫细胞浸润。
Sci Rep. 2024 Nov 11;14(1):27485. doi: 10.1038/s41598-024-78634-6.
9
Mutation Spectrum of Gene in Pompe Disease: Current Knowledge and Results of an Italian Study.庞贝病基因的突变谱:当前的知识和意大利研究的结果。
Int J Mol Sci. 2024 Aug 23;25(17):9139. doi: 10.3390/ijms25179139.
10
Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy.庞贝病治疗进展:从酶替代疗法到基因治疗。
Mol Diagn Ther. 2024 Nov;28(6):703-719. doi: 10.1007/s40291-024-00733-x. Epub 2024 Aug 12.

本文引用的文献

1
A genetic modifier of symptom onset in Pompe disease.庞贝病发病症状的遗传修饰物。
EBioMedicine. 2019 May;43:553-561. doi: 10.1016/j.ebiom.2019.03.048. Epub 2019 Mar 25.
2
The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.ACE I/D 多态性不能解释庞贝病自然病程和对酶替代治疗反应的异质性。
PLoS One. 2018 Dec 7;13(12):e0208854. doi: 10.1371/journal.pone.0208854. eCollection 2018.
3
36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.36 个月随访评估:晚发性庞贝病停止和重新开始酶替代治疗后的结果:来自瑞士庞贝病登记处的数据。
J Neurol. 2018 Dec;265(12):2783-2788. doi: 10.1007/s00415-018-9065-7. Epub 2018 Sep 19.
4
Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.法国的迟发性庞贝病:一项全国性研究的分子特征和流行病学。
J Inherit Metab Dis. 2018 Nov;41(6):937-946. doi: 10.1007/s10545-018-0243-7. Epub 2018 Aug 28.
5
Enzymatic replacement therapy in patients with late-onset Pompe disease - 6-Year follow up.晚发型庞贝病患者的酶替代疗法——6年随访
Neurol Neurochir Pol. 2018 Aug;52(4):465-469. doi: 10.1016/j.pjnns.2018.05.002. Epub 2018 May 17.
6
Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.接受酶替代疗法治疗的意大利婴儿期起病庞贝病队列的长期临床病史。
Orphanet J Rare Dis. 2018 Feb 8;13(1):32. doi: 10.1186/s13023-018-0771-0.
7
Four unreported types of glycans containing mannose-6-phosphate are heterogeneously attached at three sites (including newly found Asn 233) to recombinant human acid alpha-glucosidase that is the only approved treatment for Pompe disease.四种未报道的含6-磷酸甘露糖的聚糖在三个位点(包括新发现的天冬酰胺233)以异质性方式连接到重组人酸性α-葡萄糖苷酶上,该酶是庞贝病唯一获批的治疗药物。
Biochem Biophys Res Commun. 2018 Jan 22;495(4):2418-2424. doi: 10.1016/j.bbrc.2017.12.101. Epub 2017 Dec 20.
8
Pompe disease in Austria: clinical, genetic and epidemiological aspects.奥地利庞贝病的临床、遗传和流行病学特征。
J Neurol. 2018 Jan;265(1):159-164. doi: 10.1007/s00415-017-8686-6. Epub 2017 Nov 27.
9
A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.日本38例庞贝病患者的GAA基因分子分析及临床谱
Mol Genet Metab Rep. 2017 Oct 31;14:3-9. doi: 10.1016/j.ymgmr.2017.10.009. eCollection 2018 Mar.
10
Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease.全外显子组测序在检测婴儿型和晚发型庞贝病中的敏感性。
Mol Genet Metab. 2017 Dec;122(4):189-197. doi: 10.1016/j.ymgme.2017.10.008. Epub 2017 Oct 17.